- Home
- IMNM vs CTOS Comparison
IMNM vs CTOS Comparison
Compare IMNM & CTOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNM | CTOS |
|---|---|---|
| Founded | 2006 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IMNM | CTOS |
|---|---|---|
| Price | $28.01 | $9.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $32.80 | $9.30 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 05-08-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $6,941,000.00 | ★ $1,943,957,000.00 |
| Revenue This Year | N/A | $6.84 |
| Revenue Next Year | $1,127.34 | $4.86 |
| P/E Ratio | ★ N/A | $325.67 |
| Revenue Growth | N/A | ★ 7.86 |
| 52 Week Low | $8.67 | $5.18 |
| 52 Week High | $30.06 | $12.23 |
Technical Indicators
Market Signals| Indicator | IMNM | CTOS |
|---|---|---|
| Relative Strength Index (RSI) | 62.76 | 39.23 |
| Support Level | $18.72 | $9.34 |
| Resistance Level | N/A | $10.21 |
| Average True Range (ATR) | 1.51 | 0.43 |
| MACD | 0.15 | -0.11 |
| Stochastic Oscillator | 66.25 | 7.70 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
About CTOS Custom Truck One Source Inc.
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.